Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
Ann-Lii Cheng
Consultant or Advisory Role - Boehringer Ingelheim
Richard S. Finn
Consultant or Advisory Role - Bayer/Onyx; Bristol-Myers Squibb
Masatoshi Kudo
No relevant relationships to disclose
Josep M. Llovet
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Lilly
Honoraria - Bayer; Bristol-Myers Squibb; Lilly
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb
Shukui Qin
No relevant relationships to disclose
Marie-Aude Le Berre
No relevant relationships to disclose
Heiko Krissel
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Jordi Bruix
Consultant or Advisory Role - AngioDynamics; ArQule; Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck; Novartis; OSI Pharmaceuticals; Roche; Sanofi
Honoraria - Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb
Research Funding - AngioDynamics; ArQule; Bayer Schering Pharma; Biocompatibles; Bristol-Myers Squibb; Merck; Novartis; OSI Pharmaceuticals; Roche